BDBM362001 US10221182, Compound E1-1.7::US10221182, Compound E2-1.7

SMILES FCc1ccc(CCN2CCC(Nc3ncnc4[nH]ncc34)C(F)(F)C2)cc1

InChI Key InChIKey=FFSXIBXLZAKMOO-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 362001   

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM362001(US10221182, Compound E2-1.7 | US10221182, Compound...)
Affinity DataIC50: 22.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM362001(US10221182, Compound E2-1.7 | US10221182, Compound...)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM362001(US10221182, Compound E2-1.7 | US10221182, Compound...)
Affinity DataIC50: 38.1nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM362001(US10221182, Compound E2-1.7 | US10221182, Compound...)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM362001(US10221182, Compound E2-1.7 | US10221182, Compound...)
Affinity DataIC50: 22.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM362001(US10221182, Compound E2-1.7 | US10221182, Compound...)
Affinity DataIC50: 38.1nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM362001(US10221182, Compound E2-1.7 | US10221182, Compound...)
Affinity DataIC50: 22.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent